Fig. 3From: Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanomaAcceptability Curves Comparing the Cost-Effectiveness of 4 Competing StrategiesBack to article page